Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 Next >
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Provides Namodenoson Patent Update
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.